Waldenstrom's Macroglobulinemia
5
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 4 programs with unclassified modality
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Bristol Myers SquibbPRINCETON, NJ
1 program1
UlocuplumabPhase 1Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Eli Lilly and CompanyEnzastaurin
GenentechCC-5103
X4 PharmaceuticalsMavorixafor
Bristol Myers SquibbUlocuplumab
AmgenCarfilzomib
Clinical Trials (5)
Total enrollment: 133 patients across 5 trials
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
Start: Jul 2008Est. completion: Aug 201256 patients
Phase 2Completed
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Start: Sep 2004Est. completion: Apr 200816 patients
Phase 2Terminated
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Start: Apr 2020Est. completion: Oct 2022
Phase 1Completed
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Start: Oct 2017Est. completion: Dec 202213 patients
Phase 1Terminated
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Start: Sep 2005Est. completion: Oct 200948 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 companies competing in this space